Assessment of @entity1582 maintenance regimen of XXXX . @entity632 , @entity500 , and @entity1891 in a @entity19 @entity6872 model.

@entity632 @entity137 @entity500 @entity6872 @entity19 @entity229 @entity5 @entity786 @entity1582 @entity3600 @entity1891
A current southeastern cancer study group protocol for the treatment of multiple @entity1582 involves induction with @entity3600 , @entity786 , and @entity229 (BCP) and maintenance with either melphalan and @entity229 (MP), @entity229 , @entity632 , @entity500 , and @entity1891 (PAIV), or delayed treatment of relapsed cases following induction. These combinations of drugs are used as induction regimens to establish their chemotherapeutic effects and hematological @entity137 in the @entity19 MOPC 104E @entity6872 model. The three combinations of drugs produce rapid, reliable, and reproducible @entity5 regressions. However, MP is the only combination which consistently gives long-term disease-free survivors. This particular regimen has least @entity137 and is considered to be most effective. BCP produces complete remission with no relapses; however, long-term survivors are not observed with this combination due to early deaths because of @entity137 . Most of the @entity19 on the PAIV regimen die due to @entity137 . This combination is considered least effective. With the different drug regimens, toxic events and regressions are noted to occur at different time periods, indicating that perhaps @entity5 cells in different stages are being destroyed. Toxic events as measured by hematocrit and body weight changes always precede regression by several days. This disparity between rapid drug effects on the host and a delayed effect on the @entity5 remains unexplained but may possibly be used to advantage in designing future trials.
